48 weeks pegylated interferon alpha‐2a is superior to 24 weeks of pegylated interferon alpha‐2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection

Background/aim  Although 48‐week therapy with pegylated‐interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown.

[1]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[2]  G. Lau,et al.  Peginterferon–α2a (40 kDa) (Pegasys®) for hepatitis B , 2005 .

[3]  N. Leung,et al.  A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.

[4]  G. Lau,et al.  Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy , 2005, Gut.

[5]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[6]  W. Au,et al.  Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. , 2005, Journal of hepatology.

[7]  V. Wong,et al.  A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone , 2005, Annals of Internal Medicine.

[8]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[9]  G. Foster.  Pegylated interferons: chemical and clinical differences , 2004, Alimentary pharmacology & therapeutics.

[10]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[11]  E. Keeffe,et al.  Peginterferon vs. standard interferon in the treatment of chronic hepatitis C , 2003, Alimentary pharmacology & therapeutics.

[12]  Y. Chao,et al.  Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.

[13]  A. Bertoletti,et al.  Translation of immunological knowledge into better treatments of chronic hepatitis B. , 2003, Journal of hepatology.

[14]  D. Fong,et al.  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation , 2002, Hepatology.

[15]  E. Schiff,et al.  A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C , 2001, Hepatology.

[16]  G. Lau.  Hepatitis B infection in China. , 2001, Clinics in liver disease.

[17]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[18]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[19]  W. Hop,et al.  Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment , 1999, Hepatology.

[20]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[21]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[22]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[23]  J. Hoofnagle,et al.  Long-term remission of chronic hepatitis B after alpha-interferon therapy. , 1991, Annals of internal medicine.

[24]  A. Lok,et al.  LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1988, The Lancet.

[25]  Ally,et al.  A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .